ArticlePharmacoEconomics2010
Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
Article in PharmacoEconomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Guideline
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.Arthritis care & research · 2019Guideline
- Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature.PloS one · 2015Pooled it
- Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.Health and quality of life outcomes · 2013Trial
- Comparison between EQ-5D and SF-6D utility in rural residents of Jiangsu Province, China.PloS one · 2012Trial
- Health-related quality of life among patients with rheumatoid arthritis in Zanzibar: a prospective cohort study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab.Arthritis research & therapy · 2023Article
- Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.Frontiers in endocrinology · 2023Article
- Comparison of EuroQol-5D-3L and Short Form-6D Utility Scores in Family Caregivers of Colorectal Cancer Patients: A Cross-Sectional Survey in China.Frontiers in public health · 2021Article
- Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore.European journal of rheumatology · 2020Article
- [Cross-sectional study on clinic behavior and therapeutic status of patients with psoriatic arthritis in multi-center].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.Health and quality of life outcomes · 2017Article
- Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.Rheumatology international · 2016Observational
- Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Article
- Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
- Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis.International journal of inflammation · 2013Article
- Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values.ClinicoEconomics and outcomes research : CEOR · 2013Article
- The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis.BMC medical research methodology · 2012Article
- The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This article seeks to understand these differences using a cohort of patients with inflammatory arthritis.
objectiveTo examine the relationship between the disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, SF-6D, EQ-5D and European League Against Arthritis (EULAR) Disease Activity Score (DAS) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
methodsPatients with RA and PsA (n = 504) attending a tertiary rheumatology referral centre completed the HAQ, SF-6D and the EQ-5D before starting biological therapy and again 12 months later. The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such as the DAS, joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis to derive a mapping function and calculated utility scores from the HAQDI and the DAS 28.
resultsThe mean utility observed at baseline for RA was 0.43 for the EQ-5D and 0.54 for the SF-6D and for PsA was 0.49 for the EQ-5D and 0.57 for the SF-6D. The utility gain demonstrated by the EQ-5D was over twice that of the SF-6D. The EQ-5D scored 17% of the RA group as less than 0 (state defined as worse than death); 7% of this group remained less than 0 at follow-up. The distribution of the utility estimates was similar for both RA and PsA.
conclusionsOur findings draw attention to the impact of states worse than death on the overall distribution for the EQ-5D derived utilities and how these impact on its use in practice. EQ-5D-derived QALY changes are over twice that of the SF-6D. The implication of this for decision makers is that cost-effectiveness evaluations for treatments in this disease class are likely to be very sensitive to the choice of utility measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.